PRESS RELEASESCorMedix Appoints Paulo Costa To Its Board Of DirectorsBy GlobeNewswireSep 17, 2020 8:30 AM EDT
PRESS RELEASESCorMedix Inc. Announces FDA Acceptance For Filing And Priority Review Of New Drug Application For DefencathBy GlobeNewswireAug 31, 2020 7:47 AM EDT
PRESS RELEASESCorMedix Announces Pricing Of $20M Public Offering Of Common StockBy GlobeNewswireJul 28, 2020 9:21 AM EDT
PRESS RELEASESCorMedix Announces Proposed Public Offering Of Common StockBy GlobeNewswireJul 27, 2020 4:05 PM EDT
PRESS RELEASESCorMedix Inc. Reports Submission Of Defencath™ New Drug ApplicationBy GlobeNewswireJul 8, 2020 8:30 AM EDT
PRESS RELEASESCorMedix Inc. Announces Appointment Of Chief Financial OfficerBy GlobeNewswireMay 11, 2020 8:30 AM EDT
PRESS RELEASESCorMedix Inc. Announces Contract Extension Of Jack Armstrong As Executive Vice President And Head Of Technical OperationsBy GlobeNewswireApr 23, 2020 8:15 AM EDT
PRESS RELEASESCorMedix Completes Sale Of $5.5 Million Of NOL Tax Benefits Through New Jersey Technology Business Tax Certificate Transfer ProgramBy GlobeNewswireApr 22, 2020 8:00 AM EDT
PRESS RELEASESCorMedix Approved To Sell $5.5 Million Of NOL Tax Benefits Through The New Jersey Economic Development Authority ProgramBy GlobeNewswireFeb 3, 2020 4:19 PM EST
PRESS RELEASESCorMedix Inc. Announces FDA Grant Of Rolling Review Of Neutrolin® New Drug ApplicationBy GlobeNewswireFeb 3, 2020 8:15 AM EST
STOCKSBiotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!By Adam FeuersteinJun 19, 2015 6:00 AM EDT
MARKETSCorMedix (CRMD) Stock Gains After Receiving Positive FDA Feedback for NeutrolinBy Tony OwusuJun 17, 2015 12:38 PM EDT
MARKETSTrade-Ideas: Cormedix (CRMD) Is Today's Weak On High Relative Volume StockBy TheStreet WireJun 5, 2015 10:02 AM EDT
MARKETSTrade-Ideas: Cormedix (CRMD) Is Today's Weak On High Relative Volume StockBy TheStreet WireMay 18, 2015 10:13 AM EDT
INVESTINGThe Top-Performing Biotech Stock During a Sizzling First QuarterBy Adam FeuersteinApr 1, 2015 9:30 AM EDT
